Kidney Cancer

P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Apr 2026 --> Jul 2026

Remaining challenges include uncertainty regarding the identification of predictive biomarkers, optimization of patient selection, and integration of combination or sequencing strategies. Beyond its immediate clinical impact, belzutifan establishes a foundation for next-generation hypoxia-targeted therapies.

Importantly, clinical benefit from ICIs was negatively correlated with the TMREhigh CD8 T cell gene expression signature. These findings highlight a T cell population characterized by elevated MMP that correlates with exhaustion-like transcriptional states and poor response to immunotherapy.

In conclusion, the findings of this study elucidate the involvement of NCBP1 in the malignant progression of WT. NCBP1 enhances the stability of KPNA2 mRNA, thereby upregulating KPNA2 expression and subsequently promoting the malignant progression of WT cells.

P=N/A, N=623, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

P=N/A, N=33, Recruiting, Yale University | N=10 --> 33 | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2030

In addition, DNA methylation analysis suggested PRNRP may arise from the distal nephron, in contrast to pRCC, which appears to recapitulate proximal tubules. These findings support PRNRP as a subtype of renal cell neoplasm with a distinct epigenetic signature.

The diagnosis of renal mucinous cystadenoma is challenging with preoperative imaging, and the definitive diagnosis is made by postoperative histopathology. Surgical resection and close follow-up are necessary due to the risk of malignant transformation.

P=N/A, N=200, Recruiting, Memorial Sloan Kettering Cancer Center

In the study, miR-1251-5p/MTHFD2 axis is shown to play a vital role in RCC. Therefore, targeting this axis may be a potential therapeutic target combating the progression of RCC.

Key associations were further supported in validation analyses using GLGC lipid summary statistics. This study provides genetic evidence that lipid-lowering drug targets may have heterogeneous associations with urologic and male reproductive system cancers, supporting long-term pharmacological safety monitoring and further mechanistic and genetic validation.

The cutoff of 1.5 yielded 97.2% sensitivity and 79.8% specificity. The hRCC score is an effective clinical screening tool for detecting patients at risk for hereditary renal tumors, demonstrating high diagnostic yield and supporting targeted referral for genetic evaluation.